Breathe Well Live Well
|
FDA OKs New Maintenance Asthma Treatment Arnuity Ellipta
Medscape Other important safety information included in the highlights section of the prescribing information includes the following: "Arnuity Ellipta is contraindicated for primary treatment of status asthmaticus or acute episodes of asthma requiring intensive … |
View full post on asthma – Google News
|
FDA approves GSK's Arnuity Ellipta to treat asthma in US
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) fluticasone furoate inhalation powder, to be sold as Arnuity Ellipta, as a daily-once corticosteroid for treatment of asthma in patients aged above twelve years in the US. |
View full post on asthma – Google News
|
FDA approves GlaxoSmithKline's Arnuity Ellipta for treatment of asthma
News-Medical.net GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 … |
View full post on asthma – Google News
|
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the …
MarketWatch 20, 2014 /PRNewswire/ — GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic … |
View full post on asthma – Google News